PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29715147
OWN - NLM
STAT- MEDLINE
DCOM- 20180508
LR  - 20180508
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 5
DP  - 2018 May
TI  - Relationship and Predictive Role of the Dual Expression of FGFR and IL-8 in
      Metastatic Renal Cell Carcinoma Treated with Targeted Agents.
PG  - 3105-3110
AB  - BACKGROUND/AIM: The expression of IL-8 and FGFR has been related to prognosis and
      pathological features in renal cell carcinoma. We investigated the relationship
      between IL-8 and FGFR and the outcome in metastatic renal cell carcinoma (mRCC)
      patients. MATERIALS AND METHODS: Clinical data and histological samples of
      patients affected by mRCC and treated with targeted agents were reviewed. The
      expression of proteins was assessed using immunohistochemistry. RESULTS: FGFR1,
      FGFR2, and IL-8 were found to be expressed in 16%, 30%, and 50% of cases,
      respectively. Significant correlations were found between selected proteins. A
      lack of expression of FGFR2 and IL8 was found to be correlated with increased
      progression-free survival (PFS). The survival rate at 24 months was 44%, 38%, and
      79% of those expressing both, one, or none of the evaluated proteins,
      respectively (p=0.047). CONCLUSION: This analysis found a relationship between
      the expression of IL-8 and FGFR2 in mRCC patients treated with targeted agents.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Iacovelli, Roberto
AU  - Iacovelli R
AD  - Department of Medicine, Medical Oncology Unit, Azienda Ospedaliera Universitaria 
      Integrata Verona, Verona, Italy [email protected]
FAU - DE Tursi, Michele
AU  - DE Tursi M
AD  - Department of Oral and Medical Sciences, Oncology Unit, G. D'Annunzio University,
      Chieti, Italy.
FAU - Mosillo, Claudia
AU  - Mosillo C
AD  - Department of Radiology, Oncology and Human Pathology, Oncology Unit, Sapienza
      University of Rome, Rome, Italy.
FAU - Ciardi, Antonio
AU  - Ciardi A
AD  - Department of Radiology, Oncology and Human Pathology, Human Pathology Unit,
      Sapienza University of Rome, Rome, Italy.
FAU - Carella, Consiglia
AU  - Carella C
AD  - Department of Oral and Medical Sciences, Oncology Unit, G. D'Annunzio University,
      Chieti, Italy.
FAU - Natoli, Clara
AU  - Natoli C
AD  - Department of Oral and Medical Sciences, Oncology Unit, G. D'Annunzio University,
      Chieti, Italy.
FAU - Naso, Giuseppe
AU  - Naso G
AD  - Department of Radiology, Oncology and Human Pathology, Oncology Unit, Sapienza
      University of Rome, Rome, Italy.
FAU - Cortesi, Enrico
AU  - Cortesi E
AD  - Department of Radiology, Oncology and Human Pathology, Oncology Unit, Sapienza
      University of Rome, Rome, Italy.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Interleukin-8)
RN  - EC 2.7.10.1 (FGFR1 protein, human)
RN  - EC 2.7.10.1 (FGFR2 protein, human)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 1)
RN  - EC 2.7.10.1 (Receptor, Fibroblast Growth Factor, Type 2)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/therapeutic use
MH  - Biomarkers, Tumor/*analysis
MH  - Carcinoma, Renal Cell/drug therapy/mortality/*pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Interleukin-8/analysis/biosynthesis
MH  - Kidney Neoplasms/drug therapy/mortality/*pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Receptor, Fibroblast Growth Factor, Type 1/analysis/biosynthesis
MH  - Receptor, Fibroblast Growth Factor, Type 2/analysis/biosynthesis
MH  - Retrospective Studies
OTO - NOTNLM
OT  - *FGFR
OT  - *IL-8
OT  - *mRCC
OT  - *predictive factor
OT  - *progression-free survival
EDAT- 2018/05/02 06:00
MHDA- 2018/05/09 06:00
CRDT- 2018/05/02 06:00
PHST- 2018/02/26 00:00 [received]
PHST- 2018/03/20 00:00 [revised]
PHST- 2018/03/21 00:00 [accepted]
PHST- 2018/05/02 06:00 [entrez]
PHST- 2018/05/02 06:00 [pubmed]
PHST- 2018/05/09 06:00 [medline]
AID - 38/5/3105 [pii]
AID - 10.21873/anticanres.12569 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 May;38(5):3105-3110. doi: 10.21873/anticanres.12569.